Adbry (tralokinumab-ldrm) Injection
LEO Pharma is recalling Adbry (tralokinumab-ldrm) injection due to a lack of sterility assurance following the discovery of wool fiber.
Check your medication packaging for the affected NDC codes. If you possess the recalled product, stop using it and contact your healthcare provider for an alternative treatment or your pharmacy for return instructions.
Recall at a glance
- Quantity recalled
- 11,407 units
Why it was recalled
LEO Pharma is recalling specific lots of Adbry (tralokinumab-ldrm) injection due to a lack of assurance of sterility. The recall was initiated after particulate matter, identified as wool fiber, was discovered in one unit. This product was distributed nationwide.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Adbry, (tralokinumab-ldrm) injection
- Strength
- 300 mg
- NDC / UPC
- NDC 50222-350-91, NDC 50222-350-02
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Editorial summary by Recall Canary · summary updated 2026-06-11 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification